Active Substance: adalimumab
Common Name: adalimumab
ATC Code: L04AB04
Marketing Authorisation Holder: AbbVie Ltd
Active Substance: adalimumab
Authorisation Date: 2003-09-08
Therapeutic Area: Spondylitis, Ankylosing Arthritis, Rheumatoid Colitis, Ulcerative Crohn Disease Arthritis, Psoriatic Psoriasis Arthritis, Juvenile Rheumatoid
Pharmacotherapeutic Group: Immunosuppressants
Humira, in combination with methotrexate, is indicated for:
- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs)including methotrexate has been inadequate;
- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.
Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.
Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.
Juvenile idiopathic arthritis
Polyarticular juvenile idiopathic arthritis
Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. (for the efficacy in monotherapy see section 5.1). Humira has not been studied in patients aged less than 2 years.
Humira is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).
Ankylosing spondylitis (AS)
Humira is indicated for the treatment of adults with severe active AS who have had an inadequate response to conventional therapy.
Axial spondyloarthritis without radiographic evidence of AS
Humira is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C-reactive protein and / or magnetic resonance imaging, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs.
Humira is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Humira has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.
Humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or psoralen ultraviolet-A.
Humira is indicated for treatment of moderately to severely active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
Paediatric Crohn's disease
Humira is indicated for the treatment of severe active Crohn's disease in paediatric patients (six to 17 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications for such therapies.
What is Humira?
Humira is a medicine that contains the active substance adalimumab. It is available as a solution for injection in a pre‑filled syringe or pre‑filled pen, and a vial for use in children only, all containing 40 mg adalimumab.
What is Humira used for?
Humira is used to treat the following diseases in patients who have not responded adequately to other treatments or cannot use them:
- adults with moderate to severe active rheumatoid arthritis (a disease causing inflammation of the joints), and severe active and progressive rheumatoid arthritis;
- adults with active and progressive psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints);
- adults with axial spondyloarthritis (a disease causing inflammation and pain in the joints of the spine), including patients with:
- severe active ankylosing spondylitis;
- severe axial spondyloarthritis without evidence in the X-ray of ankylosing spondylitis but with objective signs of inflammation;
- adults with moderately to severely active Crohn’s disease (a disease causing inflammation of the gut);
- adults with psoriasis (a disease causing red, scaly patches on the skin);
- adults with moderately to severely active ulcerative colitis (a disease causing inflammation and ulcers in the lining of the gut);
- children with severe active Crohn’s disease from 6 years of age;
- patients with active polyarticular juvenile idiopathic arthritis from 2 years of age and active enthesitis-related arthritis from 6 years of age (both are rare childhood disease causing inflammation of many joints).
The medicine can only be obtained with a prescription.
How is Humira used?
Treatment with Humira must be started and supervised by a doctor who has experience in the treatment of the diseases that Humira is used to treat.
In adults, the recommended dose of Humira is 40 mg given every two weeks. For adults with Crohn’s disease and psoriasis, an initial (induction) dose of 80 mg is given followed one week later by 40 mg every two weeks (maintenance dose), while for ulcerative colitis the first two doses are 160 mg and 80 mg given two weeks apart followed by 40 mg every two weeks. Adult patients who need a more rapid response for Crohn’s disease may also need to start with these two higher doses, although this might increase the risk of side effects.
In children aged two to 12 with polyarticular juvenile idiopathic arthritis, the recommended dose is 24 mg per square metre body surface area (calculated using the patient’s height and weight), up to a maximum dose of 20 mg for children under four years old and up to 40 mg for children aged four to twelve, given every two weeks. In adolescents aged 13 to 17 with polyarticular juvenile idiopathic arthritis the dose is 40 mg every two weeks. In children and adolescents aged six to 17 with Crohn’s disease, the usual induction dose is 80 mg followed two weeks later by 40 mg every two weeks in children weighing at least 40 kg. These doses are halved in those weighing less than 40 kg, although the dose and frequency may be increased in certain circumstances. In children with enthesitis-related arthritis, the recommended dose is 24 mg per square metre body surface area, up to a maximum dose of 40 mg, given every two weeks.
Humira is given as an injection under the skin. After training, patients or their carers may inject Humira if their doctor considers it appropriate. Patients who receive Humira must be given a special alert card that summarises the safety information about the medicine. Patients may be given other medicines during treatment with Humira, such as corticosteroids (other anti‑inflammatory medicines).
For more information on how Humira is used to treat the different conditions, see the package leaflet.
How does Humira work?
The active substance in Humira, adalimumab, is a monoclonal antibody. A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen) that is found in the body.
Adalimumab has been designed to attach to a chemical messenger in the body called tumour necrosis factor (TNF). This messenger is involved in causing inflammation and is found at high levels in patients with the diseases that Humira is used to treat. By blocking TNF, adalimumab reduces the inflammation and other symptoms of the diseases.
How has Humira been studied?
Humira has been studied in five main studies of adult patients with moderate to severe rheumatoid arthritis. In four of these studies, Humira was compared with placebo (a dummy treatment), either alone or as an add-on to other anti‑inflammatory medicines and methotrexate, in over 2,000 patients. The fifth study compared the combination of Humira and methotrexate with methotrexate alone or Humira alone in 799 patients who had not taken methotrexate before.
For psoriatic arthritis, Humira was compared with placebo over 12 weeks in two main studies involving 413 adult patients. The medicines were taken alone or in combination with another anti‑inflammatory medicine.
For ankylosing spondylitis, Humira and placebo as an add-on to existing treatment were compared over 12 weeks in two main studies involving 397 adult patients. For axial spondyloarthritis without evidence in the X-ray of ankylosing spondylitis, Humira was compared with placebo over 12 weeks in a main study involving 192 adult patients who have not responded adequately or cannot take NSAIDs.
For Crohn’s disease, the effectiveness of the first two doses of Humira (induction) was compared with that of placebo in two main studies involving 624 adult patients over four weeks. Another main study involving 854 adult patients looked at the long-term effects (maintenance) of Humira over up to 56 weeks. A further main study involving 192 children aged six to 17 looked at the effectiveness of two different induction and maintenance doses of Humira, and compared the results with those seen in adults.
For psoriasis, Humira was compared with placebo over 16 weeks in a main study involving 1,212 patients. A second main study involving 271 patients compared Humira with methotrexate and with placebo over 16 weeks.
For ulcerative colitis, Humira was compared with placebo in two main studies involving 1,093 patients looking at induction and maintenance treatment with Humira. The effects of the induction dose were measured after eight weeks and the effects of maintenance treatment were assessed after 52 weeks.
For polyarticular juvenile idiopathic arthritis, Humira was compared with placebo, alone or as an add-on to methotrexate, in one main study involving 171 patients aged between four and 17 years. All of the patients received Humira for 16 weeks before being given Humira or placebo for a further 32 weeks. Humira was also investigated in a main study involving 32 children aged two to four (or over four years old but weighing under 15 kg) with polyarticular juvenile idiopathic arthritis. The study lasted 24 weeks. For enthesitis-related arthritis, Humira was compared with placebo in one main study over 12 weeks and involving 46 patients aged six years and above.
In all of the studies, the main measure of effectiveness was based on the change in symptoms.
What benefit has Humira shown during the studies?
Humira was more effective than placebo in all diseases studied.
In rheumatoid arthritis, the greatest reductions in symptoms were seen in the studies examining Humira as an add-on to methotrexate: around two thirds of the patients adding Humira had at least a 20% reduction in symptoms after six months, compared with a quarter of those adding placebo. Patients adding Humira also had less joint damage and experienced less reduction in physical function after a year. In patients who had not taken methotrexate in the past, the combination of Humira and methotrexate was also more effective than methotrexate alone.
Humira also produced a greater improvement in symptoms than placebo in studies of psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis without evidence in the X-ray of ankylosing spondylitis but with objective signs of inflammation, and induction and maintenance phases of treatment for Crohn’s disease, psoriasis and ulcerative colitis.
For polyarticular juvenile idiopathic arthritis, in patients aged between four and 17 years old around 40% of the patients receiving Humira, either alone or in combination with methotrexate, had a flare-up of arthritis, compared with around 69% of those receiving placebo. However, fewer patients receiving Humira with methotrexate developed antibodies against Humira (which can prevent its action), so the results favoured the use of Humira with methotrexate over Humira used alone. The study in younger children (aged two to four) showed that the majority of children responded well to Humira treatment and this response was maintained after 24 weeks. For enthesitis-related arthritis, treatment with Humira resulted in a larger decrease in the number of swollen and tender joints compared with placebo.
What is the risk associated with Humira?
In studies, the most common side effects with Humira (seen in more than 1 patient in 10) were respiratory tract infections (infections of the lungs and airways), leucopenia (low white blood cell counts), anaemia (low red blood cell counts), increased blood levels of lipids (fats), headache, abdominal pain (stomach ache), nausea (feeling sick) and vomiting, rash, musculoskeletal pain (pain in the muscles and bones), injection site reactions (including redness) and increased levels of liver enzymes. For the full list of all side effects reported with Humira, see the package leaflet.
Humira must not be used in patients with active tuberculosis, other severe infections, or moderate to severe heart failure (an inability of the heart to pump enough blood around the body). For the full list of restrictions with Humira, see the package leaflet.
Why has Humira been approved?
The CHMP decided that Humira’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Which measures are being taken to ensure the safe use of Humira?
A risk management plan has been developed to ensure that Humira is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Humira, including the appropriate precautions to be followed by healthcare professionals and patients.
In addition, the company that markets Humira must provide educational packs for doctors who will prescribe Humira. These packs will include information on the safety of the medicine and an alert card to be given to patients.
Other information about Humira
The European Commission granted a marketing authorisation valid throughout the European Union for Humira on 8 September 2003.
For more information about treatment with Humira, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Source: European Medicines Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.